ENTITY

Remegen (688331 CH)

54
Analysis
Health CareChina
RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.
more
Refresh
22 Jul 2022 10:18

Shanghai/​​​​​​​​​Shenzhen Northbound Connect: Weekly Moves (22 July 2022)

Overall, net outflow over the past week in the HK -Shanghai-Shenzhen Northbound Connect facilities was ~US$1.83bn, split between Shanghai (...

Logo
367 Views
Share
14 Jul 2022 09:24

Policy Interpretation of 2022 National Medical Insurance (NRDL) Negotiation

We analyzed the new policies, bidding rules, logic and impact on companies of 2022 NRDL adjustment,which will be very intense.The results will be...

Logo
215 Views
Share
08 Jul 2022 11:50

Shanghai/​​​​​​​Shenzhen Northbound Connect: Weekly Moves (8 July 2022)

Inside is a recap of movements in the HK--Shanghai/Shenzhen Northbound Connect facilities. Net inflow over the past week was ~US$1bn, split between...

Logo
466 Views
Share
17 Sep 2023 10:10

A-H Premium Weekly (Sep 15th): Postal Savings, Sinopec Corp, Shanghai Fudan, Sinopec Oilfield

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Postal Savings, Sinopec Corp, Shanghai Fudan, Sinopec...

Logo
445 Views
Share
x